It's taking me awhile to process this as it's a ma
Post# of 30027
One thing that sticks out to me is that the announcements say "exclusive license" whereby, I assume, Amarantus retains all Intellectual Property. Emerald must have the means to bring Elto and ESS to market to take on such a task. It's a good thing that "key personal" from Amarantus will be moving over to Emerald to keep these therapeutics progressing. Amarantus really is transforming into a holding company. No idea what it all means to us shareholders. Just hope everything keeps moving forward.
GC: "We will be putting a comprehensive update on $AMBS, progress with $TOMDF and plans with $EMOR. Key personnel from AMBS will be moving over to build out our programs under $EMOR umbrella. Plan remains convert all Pref/debt to common around Reg A and have one class of stock"